FEBUXOSTAT - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for febuxostat and what is the scope of patent protection?
Febuxostat
is the generic ingredient in two branded drugs marketed by Alembic, Alkem Labs Ltd, Aurobindo Pharma Ltd, Dr Reddys, Hikma, Indoco, Lupin Ltd, Macleods Pharms Ltd, MSN, Mylan, Prinston Inc, Sun Pharm, Sunshine, Torrent, Zydus Lifesciences, and Takeda Pharms Usa, and is included in sixteen NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Febuxostat has twenty-eight patent family members in fifteen countries.
There are twenty-six drug master file entries for febuxostat. Twenty-three suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for FEBUXOSTAT
International Patents: | 28 |
US Patents: | 3 |
Tradenames: | 2 |
Applicants: | 16 |
NDAs: | 16 |
Drug Master File Entries: | 26 |
Finished Product Suppliers / Packagers: | 23 |
Raw Ingredient (Bulk) Api Vendors: | 139 |
Clinical Trials: | 88 |
Patent Applications: | 1,309 |
Drug Prices: | Drug price trends for FEBUXOSTAT |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FEBUXOSTAT |
What excipients (inactive ingredients) are in FEBUXOSTAT? | FEBUXOSTAT excipients list |
DailyMed Link: | FEBUXOSTAT at DailyMed |
Recent Clinical Trials for FEBUXOSTAT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
JW Pharmaceutical | Phase 3 |
Chinese University of Hong Kong | Phase 2 |
Generic filers with tentative approvals for FEBUXOSTAT
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 80MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 40MG | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for FEBUXOSTAT
Drug Class | Xanthine Oxidase Inhibitor |
Mechanism of Action | Xanthine Oxidase Inhibitors |
Medical Subject Heading (MeSH) Categories for FEBUXOSTAT
Anatomical Therapeutic Chemical (ATC) Classes for FEBUXOSTAT
Paragraph IV (Patent) Challenges for FEBUXOSTAT
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ULORIC | Tablets | febuxostat | 40 mg and 80 mg | 021856 | 10 | 2013-02-13 |
US Patents and Regulatory Information for FEBUXOSTAT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indoco | FEBUXOSTAT | febuxostat | TABLET;ORAL | 210292-001 | Dec 30, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Zydus Lifesciences | FEBUXOSTAT | febuxostat | TABLET;ORAL | 205443-001 | Jan 9, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Torrent | FEBUXOSTAT | febuxostat | TABLET;ORAL | 211837-002 | Dec 19, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Torrent | FEBUXOSTAT | febuxostat | TABLET;ORAL | 211837-001 | Dec 19, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Msn | FEBUXOSTAT | febuxostat | TABLET;ORAL | 210461-001 | Dec 30, 2019 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Msn | FEBUXOSTAT | febuxostat | TABLET;ORAL | 210461-002 | Dec 30, 2019 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FEBUXOSTAT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | ULORIC | febuxostat | TABLET;ORAL | 021856-002 | Feb 13, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | ULORIC | febuxostat | TABLET;ORAL | 021856-001 | Feb 13, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | ULORIC | febuxostat | TABLET;ORAL | 021856-002 | Feb 13, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | ULORIC | febuxostat | TABLET;ORAL | 021856-002 | Feb 13, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | ULORIC | febuxostat | TABLET;ORAL | 021856-001 | Feb 13, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | ULORIC | febuxostat | TABLET;ORAL | 021856-001 | Feb 13, 2009 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for FEBUXOSTAT
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Krka, d.d., Novo mesto | Febuxostat Krka | febuxostat | EMEA/H/C/004773 Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Krka is indicated in adults. |
Authorised | yes | no | no | 2019-03-28 | |
Mylan Pharmaceuticals Limited | Febuxostat Mylan | febuxostat | EMEA/H/C/004374 Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Mylan is indicated in adults. |
Authorised | yes | no | no | 2017-06-15 | |
Menarini International Operations Luxembourg S.A. (MIOL) | Adenuric | febuxostat | EMEA/H/C/000777 80 mg strength:Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Adenuric is indicated in adults.120 mg strength:Adenuric is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Adenuric is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Adenuric is indicated in adults. |
Authorised | no | no | no | 2008-04-21 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for FEBUXOSTAT
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2012033941 | ⤷ Sign Up | |
European Patent Office | 2613780 | MÉTHODES DE TRAITEMENT SIMULTANÉ À BASE DE THÉOPHYLLINE ET DE FÉBUXOSTAT (METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT) | ⤷ Sign Up |
China | 103298466 | Methods for concomitant treatment of theophylline and febuxostat | ⤷ Sign Up |
South Korea | 20040101284 | ⤷ Sign Up | |
Portugal | 1488790 | ⤷ Sign Up | |
South Korea | 100981905 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FEBUXOSTAT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1020454 | SPC/GB10/019 | United Kingdom | ⤷ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/019 GRANTED TO TEIJIN LIMITED IN RESPECT OF THE PRODUCT FEBUXOSTAT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6408 DATED 14/03/2012 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22/04/2023. |
1488790 | C20140037 00152 | Estonia | ⤷ Sign Up | PRODUCT NAME: FEBUKSOSTAAT;REG NO/DATE: EU/1/08/447 23.04.2008 |
1020454 | 10C0022 | France | ⤷ Sign Up | PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421 |
1020454 | C300447 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421 |
1020454 | PA2010005,C1020454 | Lithuania | ⤷ Sign Up | PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004, 0080421 |
1020454 | PA2010005 | Lithuania | ⤷ Sign Up | PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004 20080421 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.